Mersana's phase 1 ADC cancer trial breaks free of FDA hold

31 Oct 2023
·
Deals
www.fiercebiotech.com
Phase 1Orphan DrugADCLicense out/in
Mersana's phase 1 ADC cancer trial breaks free of FDA hold
Preview
Source: FierceBiotech
Mersana Therapeutics' phase 1 antibody-drug conjugate cancer trial has broken free of the FDA's clinical hold.
In a year riddled with obstacles and adverse events, Mersana Therapeutics finally has some good news: The FDA has lifted a clinical hold on a phase 1 trial for the antibody-drug conjugate (ADC) XMT-2056.
This March, the FDA hit Mersana with the hold after the biotech voluntarily suspended the early-stage cancer trial due to a death tied to XMT-2056.
Based on trial data, Mersana is now lowering the starting dose for the phase 1 dose-escalation design, Mersana President and CEO Martin Huber, M.D., said in an Oct. 31 release.
XMT-2056, a systemically administered immunosynthen STING-agonist ADCSTING-agonist ADC, will continue being tested in patients with advanced or recurring solid tumors expressing HER-2, such as breast, gastric, colorectal and non-small cell lung cancers. The ADC has snagged orphan-drug designation from the FDA in gastric cancer.
The asset has also garnered attention from GSK. Last summer, the pharma inked a global pact with Mersana, paying $100 million upfront for the exclusive option to co-develop and commercialize XMT-2056. To date, GSK has not exercised the option.
The lifting of the hold is great news for the XMT-2056 program, but Mersana let go of another med earlier this year due to a similar FDA action. In June, the agency slapped a partial clinical hold on lead ADC UpRi. The regulatory halt came after the therapy was tied to a higher rate of serious bleeding events in treated patients with platinum-resistant ovarian cancer than in the background population. The bleeding events included five deaths.
The hold impacted both a phase 3 trial and a phase 1 dose-expansion study, halting recruitment for both.
The biotech suffered yet another blow in July, when poor efficacy results from the expansion study for UpRi sent the biotech into a tailspin and prompted layoffs to half of the biotech's team. Given the results, the company dropped the drug.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.